Serina Therapeutics (SER) AI Stock Analysis

• Market Cap: $50.95M
• Dividend Yield: N/A
• Average Volume (3M): 232.34K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.72
• Revenue Growth: 34.04%
• EPS Growth: 55.34%
• Country: US
• Employees: 12
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.66
• Shares Outstanding: 10,250,588
• 10 Day Avg. Volume: 20,866
• 30 Day Avg. Volume: 232,336
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.19
• Enterprise Value/Revenue: 467.15
• Enterprise Value/Gross Profit: 30.36K
• Enterprise Value/Ebitda: -4.87
• 1Y Price Target: $13.00
• Price Target Upside: 161.57% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 40 Neutral
• Price Target: $5.00 ▲(0.60% Upside)

Serina Therapeutics' overall stock score is significantly impacted by its poor financial performance, which is the most critical factor. The technical analysis also indicates a bearish trend, further contributing to the low score. The valuation is unfavorable due to a negative P/E ratio and lack of dividend yield. These factors collectively suggest high risk and potential instability.

Positive Factors

Innovative Drug Delivery Systems

The company's focus on innovative drug delivery systems provides a competitive edge by enhancing the efficacy and safety of existing therapies, which can lead to better patient outcomes and attract partnerships with pharmaceutical companies.

Strategic Partnerships

Strategic partnerships with pharmaceutical companies for its proprietary technologies ensure a steady revenue stream and validate the company's innovations, supporting long-term growth and stability.

Revenue Growth

A significant revenue growth rate indicates strong market demand and successful execution of business strategies, which is crucial for sustaining long-term operations and expanding market presence.

Negative Factors

Financial Instability

High liabilities and negative equity suggest financial instability, which can limit the company's ability to invest in R&D and growth initiatives, posing a risk to its long-term viability.

Negative Cash Flow

Negative cash flow from operations indicates difficulties in generating sufficient cash from core activities, which can hinder the company’s ability to fund new projects and maintain operations without external financing.

Declining Revenue and Profitability

Declining revenue and profitability highlight operational inefficiencies and a struggle to maintain market competitiveness, which can impact the company's ability to invest in future growth and innovation.

Serina Therapeutics Business Overview & Revenue Model

Company Description

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.

How the Company Makes Money

Serina Therapeutics generates revenue primarily through strategic partnerships and collaborations with pharmaceutical companies that seek to utilize its proprietary drug delivery technologies. The company may also earn income from licensing agreements for its developed products, as well as potential milestone payments and royalties from partnered drug development programs. Additionally, government grants and funding for research projects may contribute to the company's financial resources, allowing it to advance its product pipeline and expand its therapeutic offerings.

Serina Therapeutics Financial Statement Overview

Summary

Serina Therapeutics is facing severe financial challenges across all key financial statements. The income statement reflects substantial losses and declining revenue, the balance sheet is under strain due to high liabilities and negative equity, and cash flow issues point to operational inefficiencies. These factors collectively suggest a need for strategic restructuring or significant operational improvements to ensure future viability.

Income Statement

Serina Therapeutics has experienced significant volatility in revenue and profitability. The TTM data shows a drastic decline in revenue, leading to negative gross and net profit margins. This indicates severe inefficiencies and a struggle to generate sufficient income. Previous periods also reflect a trend of high losses, with EBIT and EBITDA margins persistently underperforming.

Balance Sheet

The balance sheet shows a concerning financial structure with a very low equity base and high liabilities, resulting in a negative equity in some periods. The debt-to-equity ratio is not ideal, and the return on equity is not calculable due to negative equity. This suggests high financial risk and instability.

Cash Flow

The cash flow statement highlights consistent negative free cash flow, indicating operational challenges. The operating cash flow is significantly negative, suggesting that the company struggles to generate cash from its core activities. Despite some positive financing activities, the overall cash flow position is weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	130.00K	56.00K	3.15M	500.00K	3.04M	54.00K
Gross Profit	2.00K	-138.00K	3.06M	355.00K	-110.00K	-1.23M
EBITDA	-12.47M	-10.49M	5.92M	-7.05M	-7.35M	-8.74M
Net Income	-12.59M	-11.14M	5.27M	-2.68M	-1.26M	-10.87M
Balance Sheet
Total Assets	8.94M	6.72M	11.96M	858.04K	1.84M	3.92M
Cash, Cash Equivalents and Short-Term Investments	6.04M	3.67M	7.62M	532.23K	1.31M	527.00K
Total Debt	185.00K	268.00K	4.37M	1.81M	398.17K	6.30M
Total Liabilities	7.29M	6.22M	6.61M	38.64M	36.95M	9.32M
Stockholders Equity	1.80M	641.00K	5.47M	-17.21M	-11.83M	-5.12M
Cash Flow
Free Cash Flow	-15.63M	-17.16M	-2.98M	-2.09M	-2.36M	-7.84M
Operating Cash Flow	-15.62M	-17.14M	-2.48M	-2.08M	-2.25M	-7.82M
Investing Cash Flow	-54.00K	-22.00K	-504.00K	980.94K	823.32K	-20.00K
Financing Cash Flow	15.60M	13.21M	10.07M	1.31M	1.08M	5.96M

Serina Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.97
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SER, the sentiment is Negative. The current price of 4.97 is below the 20-day moving average (MA) of 5.07, below the 50-day MA of 5.26, and below the 200-day MA of 5.25, indicating a bearish trend. The MACD of -0.10 indicates Negative momentum. The RSI at 46.36 is Neutral, neither overbought nor oversold. The STOCH value of 57.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SER.

Serina Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PDSB	50 Neutral	$47.97M	-1.11	―	―	―	25.26%
VRCA	46 Neutral	$39.48M	-0.50	776.66%	―	5.72%	55.79%
GANX	46 Neutral	$64.35M	-2.72	―	―	―	49.82%
SER	40 Neutral	$50.95M	―	45.59%	―	34.04%	55.34%
STRO	40 Neutral	$75.16M	-0.35	649.92%	―	-38.31%	-36.91%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Serina Therapeutics Corporate Events

Serina Therapeutics Secures $20M for Parkinson’s Trial

On September 9, 2025, Serina Therapeutics announced securing up to $20 million in financing to advance the registrational trial of SER-252 for Parkinson’s disease. This funding, led by Board Director Greg Bailey, MD, will support the Phase 1b clinical study under the 505(b)(2) NDA pathway. The financing structure allows flexibility in capital deployment and includes potential additional proceeds through warrant issuance. The trial aims to evaluate the safety, tolerability, and pharmacokinetics of SER-252, a novel apomorphine therapy designed for continuous dopaminergic stimulation in advanced Parkinson’s patients. The study will be conducted in the U.S. and Australia, with key milestones anticipated in 2025 and 2026.

The most recent analyst rating on (SER) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Serina Therapeutics stock, see the SER Stock Forecast page.